News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
846,272 Results
Type
Article (86474)
Company Profile (702)
Press Release (759096)
Multimedia
Podcasts (129)
Webinars (14)
Section
Business (232673)
Career Advice (4127)
Deals (39719)
Drug Delivery (129)
Drug Development (90981)
Employer Resources (198)
FDA (18103)
Job Trends (17333)
News (396444)
Policy (39746)
Tag
Academia (3000)
Academic (2)
Accelerated approval (6)
Adcomms (29)
Allergies (94)
Alliances (56828)
ALS (99)
Alzheimer's disease (1502)
Antibody-drug conjugate (ADC) (156)
Approvals (18068)
Artificial intelligence (326)
Autoimmune disease (29)
Automation (16)
Bankruptcy (405)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (119)
Biotechnology (481)
Bladder cancer (85)
Brain cancer (32)
Breast cancer (303)
Cancer (2438)
Cardiovascular disease (204)
Career advice (3534)
Career pathing (34)
CAR-T (173)
Cell therapy (490)
Cervical cancer (21)
Clinical research (73396)
Collaboration (910)
Company closure (1)
Compensation (552)
Complete response letters (30)
COVID-19 (2867)
CRISPR (48)
C-suite (265)
Cystic fibrosis (107)
Data (2271)
Decentralized trials (2)
Denatured (45)
Depression (56)
Diabetes (298)
Diagnostics (6921)
Digital health (20)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (152)
Drug pricing (128)
Drug shortages (33)
Duchenne muscular dystrophy (101)
Earnings (96663)
Editorial (45)
Employer branding (25)
Employer resources (167)
Events (130007)
Executive appointments (773)
FDA (19437)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (816)
Gene editing (119)
Generative AI (35)
Gene therapy (357)
GLP-1 (853)
Government (5160)
Grass and pollen (6)
Guidances (67)
Healthcare (20886)
Huntington's disease (25)
IgA nephropathy (31)
Immunology and inflammation (146)
Indications (30)
Infectious disease (3028)
Inflammatory bowel disease (153)
Inflation Reduction Act (11)
Influenza (57)
Intellectual property (101)
Interviews (812)
IPO (17815)
IRA (51)
Job creations (5187)
Job search strategy (2861)
Kidney cancer (11)
Labor market (42)
Layoffs (557)
Leadership (24)
Legal (10113)
Liver cancer (81)
Lung cancer (345)
Lymphoma (159)
Machine learning (7)
Management (65)
Manufacturing (352)
MASH (75)
Medical device (14638)
Medtech (14643)
Mergers & acquisitions (22445)
Metabolic disorders (790)
Multiple sclerosis (87)
NASH (23)
Neurodegenerative disease (114)
Neuropsychiatric disorders (34)
Neuroscience (2109)
NextGen: Class of 2025 (7682)
Non-profit (5082)
Now hiring (40)
Obesity (425)
Opinion (275)
Ovarian cancer (78)
Pain (99)
Pancreatic cancer (86)
Parkinson's disease (161)
Partnered (24)
Patents (250)
Patient recruitment (116)
Peanut (51)
People (65296)
Pharmaceutical (143)
Pharmacy benefit managers (21)
Phase I (22649)
Phase II (31861)
Phase III (24014)
Pipeline (1255)
Policy (172)
Postmarket research (3552)
Preclinical (10220)
Press Release (72)
Prostate cancer (113)
Psychedelics (38)
Radiopharmaceuticals (270)
Rare diseases (430)
Real estate (7392)
Recruiting (75)
Regulatory (26794)
Reports (57)
Research institute (2658)
Resumes & cover letters (649)
Rett syndrome (5)
RNA editing (5)
RSV (50)
Schizophrenia (81)
Series A (143)
Series B (91)
Service/supplier (30)
Sickle cell disease (58)
Special edition (18)
Spinal muscular atrophy (166)
Sponsored (34)
Startups (4291)
State (2)
Stomach cancer (16)
Supply chain (76)
Tariffs (46)
The Weekly (82)
Vaccines (813)
Venture capitalists (44)
Weight loss (304)
Women's health (40)
Worklife (20)
Date
Today (146)
Last 7 days (956)
Last 30 days (2810)
Last 365 days (35823)
2025 (11811)
2024 (38139)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1271)
Alabama (60)
Alaska (7)
Arizona (269)
Arkansas (14)
Asia (50128)
Australia (8829)
California (6437)
Canada (2059)
China (563)
Colorado (284)
Connecticut (303)
Delaware (160)
Europe (114970)
Florida (941)
Georgia (220)
Hawaii (1)
Idaho (64)
Illinois (630)
India (31)
Indiana (332)
Iowa (12)
Japan (169)
Kansas (111)
Kentucky (28)
Louisiana (14)
Maine (70)
Maryland (969)
Massachusetts (4945)
Michigan (248)
Minnesota (421)
Mississippi (2)
Missouri (92)
Montana (31)
Nebraska (26)
Nevada (65)
New Hampshire (70)
New Jersey (1821)
New Mexico (31)
New York (1825)
North Carolina (1130)
North Dakota (9)
Northern California (2750)
Ohio (219)
Oklahoma (15)
Oregon (48)
Pennsylvania (1422)
Puerto Rico (13)
Rhode Island (36)
South America (1652)
South Carolina (24)
South Dakota (1)
Southern California (2382)
Tennessee (104)
Texas (966)
United States (24769)
Utah (191)
Virginia (171)
Washington D.C. (69)
Washington State (605)
West Virginia (3)
Wisconsin (70)
There are 846,272 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Pliant Axes 45% of Workforce To Save Cash, Support Late-Stage Clinical Trials
Following challenges with its drug candidate bexotegrast and announcement of a limited-duration stockholder rights program, Pliant is paring back its workforce.
May 2, 2025
·
2 min read
·
Angela Gabriel
Drug pricing
Low-Price Drug Nations Catching ‘Free Ride’ on US Innovation, Report Says
No Patient Left Behind says that drug value assessments used in countries like Canada and Germany undervalue innovative medicines by 90% and mislead U.S. policymakers into thinking Americans are overpaying.
May 2, 2025
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
Kronos Accepts $35M Concentra Buyout as Walls Close In
After multiple rounds of layoffs that cut Kronos down to just 10 people, the small molecule biotech has accepted a buyout offer from Kevin Tang’s Concentra Biosciences.
May 2, 2025
·
2 min read
·
Annalee Armstrong
Layoff Tracker
BMS Closes Manufacturing Plant, Arvinas Axes One-Third of Staff
Follow along as
BioSpace
tracks job cuts and restructuring initiatives throughout 2025.
May 2, 2025
·
185 min read
·
BioSpace Editorial Staff
Press Releases
Marvel Biosciences Announces Closing of Second Tranche of Private Placement
May 2, 2025
·
5 min read
Editorial
Biomedical Innovation in Jeopardy as Kennedy Distorts, Denies Scientific Truths
As the Trump administration—including HHS Secretary Robert F. Kennedy Jr.—plays fast and loose with scientific studies and facts, there may be a more sinister force at play: censorship.
May 2, 2025
·
6 min read
·
Heather McKenzie
Government
FDA to Rehire Some Travel Staff as Lapses Begin to Show:
AP
Some 20 travel staff at the FDA, who made arrangements for the regulator’s inspectors, will be getting their jobs back, as per the
Associated Press
. Some food scientists involved in testing will also be reinstated.
May 2, 2025
·
2 min read
·
Tristan Manalac
Obesity
WHO Leaning Toward Adding Obesity Drugs for Adults to Essential Medicines List:
Reuters
In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, which the agency decided against listing in 2023, the last time the Essential Medicines list was updated.
May 2, 2025
·
2 min read
·
Tristan Manalac
Earnings
Amgen Advocates For ‘Pro-Growth Tax Policy’ Instead of Tariffs to Boost Domestic Manufacturing
Like fellow Big Pharmas Eli Lilly and Johnson & Johnson, Amgen is urging the Trump administration to consider tax policy instead of tariffs to promote domestic pharma manufacturing.
May 2, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Cartesian Therapeutics Announces New Employment Inducement Grants - May 2, 2025
May 2, 2025
·
1 min read
1 of 84,628
Next
